导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.99% | 2811/4773 |
| 近一周 | -2.60% | 2638/5462 |
| 近一月 | -5.38% | 3207/5421 |
| 近一季 | -8.22% | 2742/5209 |
| 近半年 | -3.55% | 2242/4920 |
| 近一年 | 1.42% | 2337/4366 |
| 近两年 | 42.57% | 1759/2954 |
| 近三年 | 25.78% | 1244/2253 |
| 成立以来 | 46.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.20% 3073/4961 |
13.51% 1991/5312 |
- - |
- - |
| 2025 | 21.07% 2059/4813 |
-0.06% 2044/3635 |
0.95% 2520/4076 |
19.94% 2073/4524 |
0.06% 2250/4813 |
| 2024 | 14.45% 1046/3463 |
2.90% 671/2808 |
-0.99% 887/3014 |
16.19% 1512/3129 |
-3.32% 2326/3463 |
| 2023 | -10.08% 1263/2656 |
4.45% 948/2280 |
-4.34% 1141/2385 |
-3.43% 930/2515 |
-6.80% 1924/2655 |
| 2022 | -21.50% 1038/2207 |
-13.53% 775/1919 |
6.57% 663/2016 |
-15.46% 1298/2113 |
0.76% 1454/2208 |
| 2021 | -6.50% 1010/1822 |
-2.77% 702/1255 |
2.15% 1013/1330 |
-7.30% 1039/1466 |
1.55% 883/1822 |
| 2020 | 37.89% 371/1250 |
-9.98% 736/1028 |
13.48% 615/1067 |
15.96% 183/1164 |
16.40% 174/1184 |
| 2019 | - - |
- - |
- - |
2.35% 304/850 |
6.46% 608/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝中证A100ETF联接C VS. 长安沪深300非周期A(740101) |